Delivery Order SPE2DB20D1109-SPE2DB25FP64X
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,747.93 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order falls under the company's broader...
- The U.S. Defense Logistics Agency (DLA) awarded a $58,180.33 Firm Fixed Price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of 4565964265 DUPIXENT 300 MG/2 ML PEN 2ML, a prescription pharmaceutical product, with an ultimate completion date of September 30, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025 that AmerisourceBergen holds with the...
- The Defense Logistics Agency awarded a $5,001.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract represents a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injections with a ceiling value of $4,147.68 under a firm fixed price contract type. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,706.66 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, with an ultimate completion date of September 9, 2025. This firm fixed-price, competitively awarded contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,202.22 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 MG/2 ML PEN 2ML on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply portfolio to federal customers. The place of performance is located in...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide DUPIXENT 300 MG/2 ML PEN 2ML pharmaceuticals. The award, valued at $5,921.36, has a completion date of February 28, 2024. Amerisourcebergen Drug Corp is the prime contractor on this order, which is not associated with any set-aside program. This delivery order is issued under a larger indefinite delivery contract (IDC)...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $4,059.09 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of 4563942820 DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to AmerisourceBergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC...
- The Defense Logistics Agency awarded a delivery order valued at $8,632.83 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2ML). The contract, executed on August 28, 2025, with completion targeted for August 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through competitive procurement processes. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,201.16 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 MG/2 ML pens (2 ML). This firm fixed price delivery order, awarded on August 25, 2025, represents a competitive procurement with no set-aside designation and is scheduled for completion by August 26, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP64XDelivery Order
The Defense Logistics Agency (DLA) awarded a $11,827.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The contract, awarded on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform work at its corporate office location. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 and extends through December 2026, positioning the company as a critical pharmaceutical supplier for military and federal healthcare systems. The delivery order procures DUPIXENT, a biologic pharmaceutical used for treating allergic and inflammatory conditions, supporting the DLA's medical supply chain requirements across the Defense Health Agency and other federal healthcare programs. AmerisourceBergen's extensive portfolio of pharmaceutical product distributions through federal contracts demonstrates the company's established capability to fulfill competitive procurement requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies for military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 8/26/25 |